Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 24, Issue 1, Pages 103-113
Publisher
Informa UK Limited
Online
2021-01-04
DOI
10.1080/13696998.2020.1867443
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia
- (2020) George A. Keepers et al. AMERICAN JOURNAL OF PSYCHIATRY
- Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia
- (2019) Saurabh Aggarwal et al. Journal of Comparative Effectiveness Research
- Mortality risk associated with psychological distress and major depression: A population-based cohort study
- (2018) Maria Chiu et al. JOURNAL OF AFFECTIVE DISORDERS
- Revisiting the Abnormal Involuntary Movement Scale
- (2018) John M. Kane et al. JOURNAL OF CLINICAL PSYCHIATRY
- Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials
- (2018) Marco Solmi et al. Drug Design Development and Therapy
- Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use
- (2017) Maren Carbon et al. JOURNAL OF CLINICAL PSYCHIATRY
- The Effects of Valbenazine in Participants with Tardive Dyskinesia
- (2017) Stewart A. Factor et al. JOURNAL OF CLINICAL PSYCHIATRY
- Randomized controlled trial of deutetrabenazine for tardive dyskinesia
- (2017) Hubert H. Fernandez et al. NEUROLOGY
- Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code
- (2017) Jörgen Möller et al. PHARMACOECONOMICS
- Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
- (2017) Mallik Greene et al. JOURNAL OF MEDICAL ECONOMICS
- Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
- (2016) Dhanya Vijayakumar et al. DRUGS
- The relapse rate and predictors of relapse in patients with first-episode psychosis following discontinuation of antipsychotic medication
- (2016) Suzanne Di Capite et al. Early Intervention in Psychiatry
- Discretely Integrated Condition Event (DICE) Simulation for Pharmacoeconomics
- (2016) J. Jaime Caro PHARMACOECONOMICS
- NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study
- (2015) Christopher F. O'Brien et al. MOVEMENT DISORDERS
- Special Section on Implications of CATIE: Who Are the New Users of Antipsychotic Medications?
- (2014) Marisa Elena Domino et al. PSYCHIATRIC SERVICES
- Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
- (2014) Taehwan Park et al. VALUE IN HEALTH
- Tardive Dyskinesia: Therapeutic Options for an Increasingly Common Disorder
- (2013) Leslie J. Cloud et al. Neurotherapeutics
- Comorbidities and Mortality in Bipolar Disorder
- (2013) Casey Crump et al. JAMA Psychiatry
- Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release
- (2013) Krithika Rajagopalan et al. JOURNAL OF MEDICAL ECONOMICS
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
- (2012) Stefan Leucht et al. LANCET
- Incidence of Tardive Dyskinesia with Risperidone or Olanzapine in the Elderly: Results from a 2-Year, Prospective Study in Antipsychotic-Naïve Patients
- (2011) Margaret G Woerner et al. NEUROPSYCHOPHARMACOLOGY
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
- (2011) M. Herdman et al. QUALITY OF LIFE RESEARCH
- The cost of relapse and the predictors of relapse in the treatment of schizophrenia
- (2010) Haya Ascher-Svanum et al. BMC Psychiatry
- Mortality Rates Among Patients With Schizophrenia and Tardive Dyskinesia
- (2009) Siow-Ann Chong et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule?
- (2009) R Scott Braithwaite et al. MEDICAL CARE
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment
- (2008) J. Parks et al. SCHIZOPHRENIA BULLETIN
- Treatment Costs and Health Care Utilization for Patients with Bipolar Disorder in a Large Managed Care Population
- (2008) Jeff J. Guo et al. VALUE IN HEALTH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now